Hersh Chopra, MD
Ophthalmology · Marietta, GANPI 1962463570
Payments from drug & device makers
Across 168 payments — averaging $96.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$10K
- Glaukos Corporation$1K
- AbbVie$1K
- Alcon$860
- Sight Sciences, Inc.$352
- Eyepoint US, Inc.$271
- plus $2K from 20 others
What the payments were for
- Consulting fees$10,00062%
- Food & beverage$6,19138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 4 | $10,257 |
| Glaukos Corporation | 11 | $1,181 |
| AbbVie(2 entities) | 49 | $1,177 |
| Alcon | 22 | $860 |
| Sight Sciences, Inc. | 14 | $352 |
| Eyepoint US, Inc. | 3 | $271 |
| NEW World Medical,inc. | 2 | $230 |
| Aerie Pharmaceuticals, Inc. | 6 | $220 |
| Astellas Pharma US Inc | 4 | $193 |
| Bausch & Lomb Americas Inc. | 9 | $173 |
| Biotissue Holdings Inc. | 2 | $169 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $157 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| Oyster Point Pharma, Inc. | 6 | $119 |
| Sun Pharmaceutical Industries Inc. | 4 | $118 |
| Coopervision Inc. | 1 | $105 |
| Dompe US, Inc. | 5 | $90 |
| Amgen(2 entities) | 4 | $83 |
| Tarsus Pharmaceuticals, Inc. | 2 | $70 |
| Akorn Operating Company LLC | 2 | $51 |
| Mallinckrodt Hospital Products Inc. | 3 | $44 |
| Akorn, Inc. | 1 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Thea Pharma Inc. | 1 | $25 |
| Harrow Eye, LLC | 1 | $21 |
| Ivantis, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$10,107
- RXSIGHT INJECTOR CARTRIDGE$10,107
- RXSIGHT INJECTOR HANDPIECE$10,107
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$10,107
- LIGHT ADJUSTABLE LENS (LAL)$10,000
- iDoseTR$277
- Clareon$261
- DEXYCU$250
- RADIUS$245
- Kahook Dual Blade$210
- Clearpath$210
- Ahmed Glaucoma Valve$210
- Streamline$210
- Via360$210
- ARGOS$171
- iStent Trabecular Micro-Bypass System Model iS3$160
- OMNI(R) SURGICAL SYSTEM (US)$147
- Prokera$144
- AmnioGraft$144
- iStent$133
How this compares
$16,191 in reported general payments places this provider in the 85th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 194 | $119,463 |
| VyzultaLatanoprostene Bunod | 165 | $86,604 |
| LumiganBimatoprost | 142 | $82,586 |
| RestasisCyclosporine | 36 | $42,375 |
| CombiganBrimonidine Tartrate/Timolol | 93 | $34,369 |
| RocklatanNetarsudil Mesylat/Latanoprost | 45 | $24,616 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 65 | $13,252 |
| Latanoprost | 879 | $11,944 |
| Alphagan PBrimonidine Tartrate | 23 | $11,730 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 443 | $9,336 |
| Brinzolamide | 23 | $8,120 |
| Prednisolone Acetate | 187 | $7,449 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $6,738 |
| Brimonidine Tartrate | 427 | $5,567 |
| Cyclosporine | 13 | $5,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,177 | $171,060294 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $220 | $144,078239 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $173 | $86,604165 claims |
| AlconSimbrinza | $860 | $6,73822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Marietta
- Robert StoltzMarietta$3.9M
- Lakshmana KooragayalaMarietta$1.4M
- Annal MelethMarietta$446K
- Puneet PandaMarietta$185K
- Rajesh RangarajMarietta$23K
- Dennis MarcusAugusta$9.2M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.